The 2017/18 influenza season was a very unusual one
The season was very prolonged and characterised by a high number of influenza cases, among which influenza B was dominant.
This week, Statens Serum Institut publishes a joint statement about the 2017/18 influenza season.
In many ways, the season was very unusual. The season was prolonged and characterised by a very high level of influenza activity. This was reflected in a very high number of patients who had influenza detected, an elevated number of hospital admissions and a substantial excess mortality among adults and elderly people.
The dominant virus was influenza B of the Yamagata line. Nevertheless, quite a few influenza A cases were also seen, particularly towards the end of the season.
“It is unusual for influenza B to be the dominant influenza virus. Influenza B is often seen after influenza A towards the end of the season, and normally does not lead to hospital admissions and deaths among the elderly", notes consultant Tyra Grove Krause from the Department of Infectious Disease Epidemiology and Prevention at Statens Serum Institut.
Low vaccine effect
The 2017/18 season was also characterised by a lower vaccine effect than expected. This was, among others, the case because the influenza B virus in the vaccine and the influenza B virus that was circulating in the population did not coincide. Despite this, the vaccinations prevented 22% of the influenza A infections in elderly people above 65 years of age and 30% of the influenza B infections.
The vast majority (95%) of the patients who were hospitalised with influenza belonged to one of the influenza risk groups. That means that they were either chronically ill or older than 65 years of age. This underlines the importance of preventing influenza in these groups through vaccination. Every year, influenza vaccination is offered free of charge to these groups from October through December. Even so, the majority of the admitted patients (63%) had not received influenza vaccination.
“Even though influenza vaccination in this season had a lower effect than we had expected, vaccination remains our best weapon in the fight against influenza. Even when the effect is low, vaccination prevents disease, hospitalisations and deaths in the population. Additionally, influenza often runs a milder course even if you do fall ill after being vaccinated”, explains Tyra Grove Krause.
Next season’s trivalent vaccine, the contents of which is recommended by the WHO, will also not contain influenza B/Yamagata. This is so because the virus is not expected to enter circulation as this year, owing to the massive spreading of infection in this season.
Tyra Grove Krause,
Head of Department, Senior Consultant, MD, PhD, specialist in Public Health Medicine,
Epidemiologisk Infek.bered-Ledelse stab / Epidemiologisk Infektionsberedskab
T. +45 32688613 @. email@example.com View profile